Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study
Arthritis Care & Research , 07/05/2012
Singer O et al. – Although some symptomatic subjects had new MRI abnormalities, RAMRIS scores did not significantly change. The incidence of Aromatase Inhibitors associated musculoskeletal syndrome is over 50% with most women developing symptoms by 8 weeks. The key finding in symptomatic women was focal tenosynovitis of the hands and feet, without evidence of autoimmune disease or systemic inflammation. Later stage cancer and poorer quality of life were predictive of symptom development.
